APA (7th ed.) Citation

Xia, Z., Leng, Y., Fang, B., Liang, Y., Li, W., Fu, C., . . . Cai, Z. (2023). Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): A randomised, double-blinded, placebo-controlled, phase 3 trial. BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-11489-8

Chicago Style (17th ed.) Citation

Xia, Zhongjun, et al. "Aponermin or Placebo in Combination with Thalidomide and Dexamethasone in the Treatment of Relapsed or Refractory Multiple Myeloma (CPT-MM301): A Randomised, Double-blinded, Placebo-controlled, Phase 3 Trial." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-11489-8.

MLA (9th ed.) Citation

Xia, Zhongjun, et al. "Aponermin or Placebo in Combination with Thalidomide and Dexamethasone in the Treatment of Relapsed or Refractory Multiple Myeloma (CPT-MM301): A Randomised, Double-blinded, Placebo-controlled, Phase 3 Trial." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-11489-8.